

Investor Relations | Hologic

Hologic Ships 500th Delphi® Bone Densitometer

Additional 150 Systems Upgraded to Delphi Capabilities

PRNewswire
BEDFORD, Mass.

Hologic, Inc. (NASDAQ: HOLX) a leading provider of specialized imaging equipment for women's health and general radiographic purposes, today announced the shipment of its five hundredth Delphi series x-ray bone densitometer. Unveiled in March 2000, Hologic's Delphi® series, with its unique Instant Vertebral Assessment™ (IVA) technology, is the only bone densitometry system that effectively integrates the assessment of the two strongest risk factors for osteoporotic fracture: low bone mineral density and the presence of a vertebral fracture.

Hologic's IVA technology enables clinicians to perform a rapid, low-dose evaluation of the spine in a single office visit during a routine bone densitometry exam. The high-resolution, single-energy images obtained with IVA visually reveal spinal fractures, which substantially increase the risk of future fracture, and thereby affect a clinician's therapeutic decisions. Prior to the introduction of Delphi, spine fractures were rarely evaluated in clinical osteoporosis assessment, primarily due to the inconvenience and high radiation dose associated with obtaining conventional x-ray films. Delphi with IVA provides a simple, point of care tool for vertebral assessment, with only 1% of the radiation dose of standard radiographic assessment.

Hologic's 500th Delphi system was installed at the Colorado Center for Bone Research, headed by Paul Miller, M.D. Dr. Miller, a world-renowned osteoporosis researcher, is the founding President of the International Society for Clinical Densitometry, and a Clinical Professor of Medicine at the University of Colorado Health Sciences Center, Denver, CO. The system is the second Delphi installed at Dr. Miller's institution, where IVA is utilized as an integral part of clinical patient evaluation. Commenting on the utility of IVA, Dr. Miller said "The importance of incorporating vertebral assessment as part of a standard bone density examination is widely recognized among physicians. Studies show that utilizing bone density results alone misses approximately 30% of patients in need of therapy. Because many spine fractures are asymptomatic, only one in four is clinically recognized. However, the presence of a fracture significantly increases a woman's risk of future fracture. A patient with a spine fracture is twice as likely to suffer a hip fracture and 5 times more likely to suffer a subsequent spine fracture. Given that we now have a number of effective therapies for treating osteoporosis, the identification of patients with existing fractures provides a simple means of improving patient care."

Jack Cumming, Hologic's President and CEO, said, "We are extremely pleased with the market's acceptance of Hologic's latest technical innovation in the field of bone densitometry. Hologic's reputation for providing innovative and quality solutions for the detection and monitoring of osteoporosis has been instrumental in the Company's ability to maintain its dominant position in this field. Hologic's commitment to research and development has enabled us to make great strides in our mission to improve the quality of women's healthcare worldwide."

Commenting on this milestone, Dr. Eric von Stetten, Vice President and General Manager, Osteoporosis Assessment, said, " Hologic's Delphi series, with Instant Vertebral Assessment, is the industry's premier technology for identifying women at risk for osteoporosis-related fractures. With the advent of new osteoporosis therapies and the aging of the "baby boomer" population, the need for bone density systems that provide a comprehensive assessment of the two greatest risk factors for future fracture has never been greater. We have met this need with the introduction of our Delphi series of bone densitometers."

In addition to the 500 Delphi systems now installed, a total of 150 densitometry systems previously installed by Hologic have been upgraded to Delphi capabilities, including IVA. Worldwide, an installed base of over 4,000 Hologic systems can be upgraded to Delphi, providing the means for widespread adoption of this important new standard of care. In the United States, the diagnostic advantages offered by IVA are accompanied by increased reimbursement (\$67 for IVA), improving the economics of osteoporosis testing. Dr. von Stetten elaborated further, stating "The popularity of Hologic's Delphi systems and upgrades to Delphi capabilities are driven by the diagnostic benefit, but the additional reimbursement allows many who could not afford densitometry equipment to offer this important service. Expanded testing is important, because many of the 5 million osteoporotic fractures occurring worldwide each year could be prevented with testing and appropriate treatment."

About Hologic, Inc.

Hologic, Inc. is dedicated to developing and delivering proprietary X-ray and ultrasound systems that incorporate direct-to-digital radiographic imaging technology for both women's health and general radiographic applications. Hologic's business divisions include: the Hologic Radiographic Systems division encompassing general and digital radiography systems; Direct Radiography Corp., a wholly owned subsidiary and manufacturer of state-of-the-art proprietary flat panel technology called DirectRay; the Hologic Bone Densitometry division; the LORAD division, a wholly-owned

subsidiary specializing in state-of-the-art breast imaging and minimally invasive breast biopsy systems; and Fluoroscans Imaging, a wholly owned subsidiary, manufacturing and marketing state-of-the-art, low intensity, real time X-ray imaging devices.

For more information on Hologic, please visit the Company's website at <http://www.hologic.com/>.

Forward Looking Disclaimer

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, Hologic's continuing losses and ability to fund those losses as well as other working capital requirements; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the early stage of market development for digital X-ray products; risks relating to the Company's reliance on a single source of supply for some key components of its products; risks related to ongoing litigation; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

MAKE YOUR OPINION COUNT - Click Here

<http://tbutton.prnewswire.com/prn/11690X84856469>

SOURCE: Hologic, Inc.

Contact: Glenn P. Muir, Executive Vice President & CFO, or Marianne E. Ritchie, Manager, Investor Relations, both of Hologic, Inc., +1-781-999-7300

Web site: <http://www.hologic.com/>

<https://investors.hologic.com/news?item=179>